Therapeutic Area | MeSH |
---|---|
infections | D007239 |
urogenital diseases | D000091642 |
immune system diseases | D007154 |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
ZERIT | Bristol Myers Squibb | N-020412 DISCN | 1994-06-24 | 5 products, RLD |
ZERIT | Bristol Myers Squibb | N-020413 DISCN | 1996-09-06 | 1 products, RLD |
ZERIT XR | Bristol Myers Squibb | N-021453 DISCN | 2002-12-31 | 4 products |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
acquired immunodeficiency syndrome | EFO_0000765 | D000163 | B20 |
hiv infections | EFO_0000764 | D015658 | B20 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hiv infections | D015658 | EFO_0000764 | B20 | 16 | 52 | 36 | 21 | 32 | 152 |
Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | — | 2 | 6 | 6 | 1 | 13 |
Hiv | D006678 | — | O98.7 | 1 | 2 | 2 | 6 | 2 | 12 |
Tuberculosis | D014376 | EFO_0000774 | A15-A19 | 1 | 3 | 2 | 1 | — | 6 |
Lipodystrophy | D008060 | HP_0009125 | E88.1 | — | 2 | — | 3 | — | 5 |
Cryptococcal meningitis | D016919 | EFO_0007228 | B45.1 | — | — | — | 1 | 1 | 2 |
Lactic acidosis | D000140 | HP_0003128 | E87.20 | — | 1 | 1 | 1 | — | 2 |
Hiv-1 | D015497 | — | — | — | — | — | 1 | — | 1 |
Hepatitis | D006505 | HP_0012115 | K75.9 | — | — | — | 1 | — | 1 |
Exanthema | D005076 | HP_0000988 | — | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Malaria | D008288 | EFO_0001068 | B54 | — | — | 1 | — | — | 1 |
Aids-associated nephropathy | D016263 | EFO_0007313 | — | — | — | 1 | — | — | 1 |
Diarrhea | D003967 | HP_0002014 | R19.7 | — | — | 1 | — | — | 1 |
Aids dementia complex | D015526 | EFO_0002608 | — | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hiv seropositivity | D006679 | — | — | — | 1 | — | — | — | 1 |
Metabolic diseases | D008659 | EFO_0000589 | E88.9 | — | 1 | — | — | — | 1 |
Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | 1 | — | — | — | 1 |
Nutrition disorders | D009748 | EFO_0001069 | — | — | 1 | — | — | — | 1 |
Insulin resistance | D007333 | HP_0000855 | E88.819 | — | 1 | — | — | — | 1 |
Hyperlactatemia | D065906 | — | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Pregnancy | D011247 | EFO_0002950 | Z33.1 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hepatitis c | D006526 | — | B19.2 | — | — | — | — | 1 | 1 |
Drug common name | Stavudine |
INN | stavudine |
Description | Stavudine is a nucleoside analogue obtained by formal dehydration across positions 2 and 3 of thymidine. An inhibitor of HIV-1 reverse transcriptase It has a role as an antimetabolite, an EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor and an antiviral agent. It is an organic molecular entity, a nucleoside analogue and a dihydrofuran. It is functionally related to a thymine. |
Classification | Small molecule |
Drug class | antineoplastics; antivirals (zidovudine group) (exception: edoxudine) |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | Cc1cn([C@H]2C=C[C@@H](CO)O2)c(=O)[nH]c1=O |
PDB | — |
CAS-ID | 3056-17-5 |
RxCUI | — |
ChEMBL ID | CHEMBL991 |
ChEBI ID | 63581 |
PubChem CID | 18283 |
DrugBank | DB00649 |
UNII ID | BO9LE4QFZF (ChemIDplus, GSRS) |